https://t.co/6C6o5xtgQP APOEE2/2 carriers have exceptionally low odds of developing AD vs APOE4/4 genotype (OR 0.004, with allele dose response). If only this could be translated into treatment! Current beta amyloid/Tau mAb approaches seems .......2/
STAT news coverage here: https://t.co/7W0AsGWAB3
MGH also set up fundraising to support the awesome authors! @ytquiroz Here: https://t.co/GdAIMq1AvB
Two groundbreaking work highlighting the critical role of APOE on AD. Here: https://t.co/ZFaBlcVKkA And here: https://t.co/Ct2YGAy8jX Great work for all the AD patients waiting for a treatment!